Aurinia Pharmaceuticals (AUPH) EPS (Weighted Average and Diluted): 2020-2025
Historic EPS (Weighted Average and Diluted) for Aurinia Pharmaceuticals (AUPH) over the last 6 years, with Sep 2025 value amounting to $0.23.
- Aurinia Pharmaceuticals' EPS (Weighted Average and Diluted) rose 130.00% to $0.23 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.56, marking a year-over-year increase of 473.33%. This contributed to the annual value of $0.04 for FY2024, which is 107.41% up from last year.
- As of Q3 2025, Aurinia Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $0.23, which was up 43.75% from $0.16 recorded in Q2 2025.
- In the past 5 years, Aurinia Pharmaceuticals' EPS (Weighted Average and Diluted) ranged from a high of $0.23 in Q3 2025 and a low of -$0.40 during Q1 2021.
- Over the past 3 years, Aurinia Pharmaceuticals' median EPS (Weighted Average and Diluted) value was $0.01 (recorded in 2024), while the average stood at $0.01.
- As far as peak fluctuations go, Aurinia Pharmaceuticals' EPS (Weighted Average and Diluted) crashed by 316.67% in 2021, and later spiked by 1,500.00% in 2025.
- Over the past 5 years, Aurinia Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.25 in 2021, then grew by 28.00% to -$0.18 in 2022, then declined by 5.56% to -$0.19 in 2023, then skyrocketed by 105.26% to $0.01 in 2024, then skyrocketed by 130.00% to $0.23 in 2025.
- Its EPS (Weighted Average and Diluted) stands at $0.23 for Q3 2025, versus $0.16 for Q2 2025 and $0.16 for Q1 2025.